Compare USAS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USAS | NMRA |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | USAS | NMRA |
|---|---|---|
| Price | $5.63 | $2.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $4.08 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 4.5M | 1.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,867,000.00 | N/A |
| Revenue This Year | $20.47 | N/A |
| Revenue Next Year | $91.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.95 | $0.61 |
| 52 Week High | $6.24 | $3.25 |
| Indicator | USAS | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 60.76 |
| Support Level | $4.89 | $1.50 |
| Resistance Level | $5.39 | $1.93 |
| Average True Range (ATR) | 0.35 | 0.18 |
| MACD | -0.08 | 0.04 |
| Stochastic Oscillator | 57.53 | 71.15 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.